FindTrial
Sign In

Evaluation of Anti-Mullerian Hormone as a predictive marker in ovarian reserve and assisted reproductive technology

Evaluation of Anti-Mullerian Hormone as a predictive marker in ovarian reserve and assisted reproductive technology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-15005867
Enrollment
Unknown
Registered
2015-01-20
Start date
2015-02-01
Completion date
Unknown
Last updated
2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

women undergoing IVF cycles

Interventions

Gold Standard:Clinical symdroms
Index test:Anti-Mullerian&#32
Hormone,&#32
AMH

Sponsors

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: infertility women who attend Assisted Reproductive Technology centre, Prince of Wales Hospital for In-vitro fertilization (IVF) programme

Exclusion criteria

Exclusion criteria: patients who are unwilling to participate

Design outcomes

Primary

MeasureTime frame
To determine the efficacy of AMH to predict the poor ovarian responder and over ovarian responder.;—

Secondary

MeasureTime frame
the relationship between AMH and the ovarian response after ovarian stimulation in IVF cycle;the relationship between AMH and other baseline ovarian reserve markers on assessing the ovarian reserve and ovarian response in IVF cycle;—

Countries

China

Contacts

Public ContactDr. Grace Kong

Department of Obstetrics &Gynaecology, Prince of Wales Hospital

gracekong@cuhk.edu.hk+852 2632 2996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026